Cognition Therapeutics, Inc. ( (CGTX) ) has released its Q2 earnings. Here is a breakdown of the information Cognition Therapeutics, Inc. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Cognition Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for age-related degenerative diseases and disorders of the central nervous system and retina, utilizing proprietary biology and chemistry platforms. The latest earnings report for the quarter ended June 30, 2025, highlights the company’s ongoing financial challenges, with a net loss of $6.7 million for the quarter and $15.2 million for the first half of the year. Despite these losses, the company continues to advance its lead product candidate, zervimesine (CT1812), and has generated $12.2 million in grant income for the first half of 2025. The company’s cash and cash equivalents decreased to $10.7 million as of June 30, 2025, from $25 million at the end of 2024, reflecting the need for additional funding to support its operations and growth strategy. Cognition Therapeutics remains focused on securing additional capital through public offerings, private placements, and strategic collaborations to sustain its operations and advance its product development pipeline.